Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Terminated 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 33Gastrointestinal 33Breast 13Gynecologic 11Head & Neck 9Other hematologic neoplasm 6Lymphoid 6Other solid neoplasm 5Tumor-Agnostic 4CNS 4Sarcoma 3Genitourinary 2Dermatologic 1

Conditions

Neoplasm Metastasis 3Neoplasms 1

Interventions

pembrolizumab 24Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 19Paclitaxel 11Standard of Care 10Bevacizumab 10atezolizumab 9Carboplatin 9Nivolumab 8Cisplatin 8Blood Specimen Collection 8Surveys and Questionnaires 7Capecitabine 7Radiosurgery 6Pemetrexed 6Gemcitabine 6Cyclophosphamide 6durvalumab 5Taxes 5Irinotecan 5trastuzumab deruxtecan 4olaparib 4niraparib 4cabozantinib 4X-Rays 4Radiotherapy 4Oxaliplatin 4Leucovorin 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Drug Therapy × Tumor-Agnostic × 90 days × Clear all
NCT06803680 2026-05-22

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

BeOne Medicines

Phase 1 Recruiting
90 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT07498725 2026-03-27

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

LARKSPUR BIOSCIENCES, INC.

Phase 1/2 Not yet recruiting
120 enrolled
Tumor-Agnostic

Neoplasms

NCT06540066 2026-03-16

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

BeOne Medicines

Phase 1 Terminated
35 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05935098 2026-03-13

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

BeOne Medicines

Phase 1 Terminated
99 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡